A Phase 4 Comparative Trial of Benzathine Penicillin G 2.4 Million Units Administered as a Single Dose versus Three Successive Weekly Doses for Treatment of Early Syphilis in Subjects with or without HIV Infection
The purposes of this study are to compare the effect of 1 dose of Benzathine Penicillin G (BPG) to 3 weekly doses of BPG in all subjects; and to determine whether the effects of 1 dose of BPG or 3 weekly doses of BPG are different in HIV-infected and HIV-uninfected subjects.
Adults 18 years of age and older are needed for a study assessing syphilis treatment. This study is being conducted by Dr. Teresa Batteiger at Indiana University School of Medicine. The study takes place in the Bell Flower Clinic of the Fifth Third Office Building, next to Eskenazi Hospital.
This study will compare the effect of one dose to three doses (one dose a week for three weeks in a row) of medication normally given for treatment of Syphilis in individuals with or without HIV infection. Volunteers must have early syphilis but have not been treated yet. You will be paid for your participation. The total duration of participation is 12 months, with 8 visits over that time. Risks will be disclosed prior to study enrollment.
For information or to see if you qualify, call Lora at 317-274-8453.
- IRB Number: 1804212716
- Research Study Identifier: TX8919
- Principal Investigator: Teresa Batteiger, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required